Pharmaxis announced the launch of Aridol (mannitol inhalation powder) Bronchial Challenge Test Kit. Aridol is a single-use test indicated to assess bronchial hyperresponsiveness in patients ≥6 years who do not have clinically apparent asthma. The Aridol Bronchial Challenge Test requires patients to inhale, from a hand-held device, increasing doses of dry powder mannitol, which causes airways to narrow and contract when airway inflammation is present. The doses are contained in capsules that are administered at one-minute intervals until a positive response is achieved or until all the capsules have been inhaled, indicating a negative result. The Aridol test takes approximately 20 minutes to administer and requires a 15% reduction in FEV1 from baseline for a positive test.
Aridol should not be used as a stand-alone test to assess asthma or as a screening test for asthma, but as part of a physician’s overall assessment of asthma.
For more information call (610) 363-5120 or visit www.pharmaxis.com.